Clinical Trial

Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess safety and efficacy in patients with with Refractory skin ulcer no response to existing therapy. The main measures it aims to answer are: * Investigation of adverse events * Changes in clinical testing data * Changes in vital signs Participants will have one PAL-222 transplanted to the ulcer site. Researchers will compare before and after the transplantation to see if any safety issues are recognized.
Trial Details
NCT Number NCT07016438
Lead Sponsor PharmaBio Corporation
Conditions Refractory Skin Ulcer
Enrollment 6 participants
Start Date 2025-04-15
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-11